Compare Boston Scientific Corporation (BSX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Xcel Energy Inc — how do they compare? Boston Scientific Corporation trades at $43.29 (market cap $66.37B), while Xcel Energy Inc trades at $79.88 (market cap $50.05B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Xcel Energy Inc pays a 2.96% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | XEL | |
|---|---|---|
Market Cap | $66.37B | $50.05B |
Sector | Health | Utilities |
52-Week High | $108.14 | $83.91 |
52-Week Low | $42.63 | $68.33 |
Enterprise Value | $75.94B | $87.49B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
XEL trades at $80.48, up 0.52% today, with a bullish technical signal and strong analyst consensus. Recent earnings show a Q1 2026 beat, while Q3 and Q4 2025 missed expectations. The company's $60 billion capital plan through 2030 aims to capitalize on rising electricity demand, supporting projected EPS growth. Cash flow trends show improving net cash flow, reaching $637 million in 2026. The stock is near its 52-week high, with a consensus price target of $91.88 implying potential upside.
Outlook is positive due to robust capital investment and sector tailwinds, but regulatory pushback and high valuation pose risks. Analyst sentiment is predominantly bullish, with 63% buy ratings. Investors should weigh growth prospects against execution risks and current premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
